INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2021

Semaglutide 2.4 mg weekly combined with lifestyle intervention produced significantly greater weight reduction than placebo in adults with overweight/obesity and type 2 diabetes.

In this 68-week trial, 1210 adults with type 2 diabetes and a BMI of at least 27 kg/m2 were randomized to receive weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo, alongside a lifestyle intervention. Estimated mean bodyweight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo (difference -6.2 percentage points, 95% CI -7.3 to -5.2; p<0.0001). Significantly more patients taking semaglutide 2.4 mg achieved at least 5% weight reduction compared to placebo (68.8% vs 28.5%; OR 4.88, 95% CI 3.58 to 6.64; p<0.0001). Adverse events, particularly gastrointestinal events, were more common with semaglutide 2.4 mg (87.6% total, 63.5% gastrointestinal) than with placebo (76.9% total, 34.3% gastrointestinal).

Study type
Randomized, double-blind, double-dummy, placebo-controlled trial
Who was studied
1210 adults with overweight or obesity and type 2 diabetes
What was measured
Percentage change in bodyweight and achievement of at least 5% weight loss at 68 weeks

THE PAPER

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, STEP 2 Study Group. Lancet, 2021.

PubMed 33667417 ↗DOI 10.1016/s0140-6736(21)00213-0 ↗

Diabetes & blood sugarWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.